Waiting on Vasopressin: Early Escalation Fails to Improve Septic Shock Survival

One of the most persistent dilemmas in intensive care medicine has just received a definitive answer. A large randomized trial led by researchers at Intermountain Health in Salt Lake City has found that starting the hormone medication vasopressin earlier in patients with life-threatening septic shock does not improve survival, shorten hospital stays, or speed recovery compared with waiting to see whether a patient’s condition worsens. The study, published online on October 14 in JAMA, offers clinicians something they have lacked for decades: rigorous evidence on the timing of one of the most common escalation decisions made at the bedside of the sickest patients in the hospital.

Sepsis is among the most common and deadliest medical emergencies in the United States, affecting an estimated 1.7 million Americans each year. It arises when the body’s response to an infection turns against its own tissues and organs, triggering a cascade of inflammation that can lead to widespread organ dysfunction. Septic shock represents the most severe form of this syndrome. In these patients, the inflammatory response causes blood vessels to dilate excessively, and blood pressure falls so low that blood and oxygen can no longer reach vital organs such as the brain, kidneys, and heart in sufficient quantities. Without rapid intervention, the result is often multi-organ failure and death. Septic shock contributes to an estimated one in three hospital deaths nationwide, making it one of the most consequential conditions in modern medicine.

The standard approach to septic shock involves two parallel strategies. Clinicians administer antibiotics and control the source of the infection, while simultaneously using medications called vasopressors to constrict blood vessels and raise blood pressure to a level that keeps organs perfused. First-line vasopressors are agents related to adrenaline, such as norepinephrine, which act on receptors that tighten blood vessels and support cardiac output. But when these first-line drugs are not enough, physicians turn to a second agent: vasopressin, a naturally occurring hormone that raises blood pressure through a different mechanism, constricting vessels via vasopressin receptors rather than adrenergic ones. Vasopressin is also, notably, an expensive infusion, and its use consumes significant hospital resources.

What has never been clear is when to add it. Some critical care clinicians begin vasopressin relatively early, as soon as a patient’s blood pressure starts to become difficult to control on norepinephrine alone. Others wait, reserving the drug for patients who require higher doses of the first-line agents before escalation. Both strategies have coexisted in intensive care units around the world, guided by physiological reasoning rather than direct comparative evidence. “For years, clinicians have known what medications to use for septic shock, but there has been little evidence about when to add vasopressin after initial vasopressor therapy,” said Ithan D. Peltan, MD, principal investigator of the study and an Intermountain Health critical care physician and researcher.

The new findings come from the Vasopressin for Septic Shock Pragmatic (VASSPR) Trial, which evaluated the two treatment strategies across 13 Intermountain Health hospitals in Utah and Idaho between February 2024 and July 2025. The trial enrolled 3,959 adults with septic shock, making it one of the largest studies of its kind in the field. Rather than randomizing individual patients, the investigators used a hospital-level design, comparing periods in which hospitals recommended starting vasopressin earlier against periods in which they recommended waiting until a patient’s shock potentially worsened. Researchers then evaluated outcomes over the following 28 days.

The result was striking in its simplicity: no meaningful differences between the groups. Survival, the amount of time patients spent alive and out of the hospital, and other measures of recovery were similar regardless of when vasopressin treatment was initiated. The trial did observe slightly higher rates of cardiogenic shock in the early-treatment group, a finding that may reflect physiological differences in how the two strategies affect the heart, but the researchers determined that this difference had no meaningful impact on patient-centered outcomes such as survival and recovery.

“The question wasn’t whether vasopressin works. We already know it can help raise blood pressure in patients with septic shock. The question is when it should be added to other vasopressors,” Dr. Peltan explained. “This trial directly answers a common bedside question that affects thousands of patients every year: is it safe to wait to see if a patient’s sepsis gets worse before giving them costly infusions they may not need? Our study found that it is.”

The implications extend beyond the specific question of vasopressin timing. Sepsis is a leading cause of intensive care unit admissions and one of the most expensive conditions treated in U.S. hospitals, costing billions of dollars to treat annually. If hospitals can safely adopt a more conservative approach to escalation, waiting to confirm that a patient truly needs a second vasopressor before starting it, the savings in medication costs, infusion equipment, and nursing workload could be substantial, all without compromising patient outcomes. In an era of intense pressure on hospital resources, evidence that supports restraint is a rare and valuable commodity.

“In healthcare, findings that show a treatment doesn’t need to be used earlier are often just as important as findings that support a new therapy,” said Dr. Peltan. “Our study suggests that hospitals can take a more conservative approach, helping deliver effective care while using resources wisely.” Researchers say the findings will help inform future clinical practice guidelines and provide physicians with greater confidence when making treatment decisions for patients with septic shock, replacing habitual variation between institutions with a shared, evidence-based standard.

Beyond its clinical findings, the VASSPR trial is also an example of an important advancement in how health systems conduct research. By embedding large-scale clinical trials within routine patient care, researchers can answer important questions efficiently in real-world settings, enrolling broad patient populations at a fraction of the cost and time required by traditional trials. The infrastructure developed for the study is already being used to launch additional clinical trials within Intermountain Health, designed to address the challenging questions that physicians and nurses encounter daily at the bedside. “Trials like this one have the potential to make meaningful changes and guide us on difficult questions that are hard to answer with traditional clinical trials,” said Dr. Peltan. For the hundreds of thousands of patients who develop septic shock each year, that means the evidence base guiding their care is finally catching up with the urgency of their condition.

Subject of Research: Timing of vasopressin initiation for the treatment of septic shock

Article Title: New study finds escalating treatment earlier for patients with life-threatening septic shock doesn’t improve survival or recovery

Article References: New study finds escalating treatment earlier for patients with life-threatening septic shock doesn’t improve survival or recovery. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: septic shock, sepsis, vasopressin, vasopressors, critical care, randomized controlled trial, VASSPR trial, Intermountain Health, JAMA, blood pressure, intensive care, clinical guidelines